
<!DOCTYPE html>
<html xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns="http://www.w3.org/TR/REC-html40">
<head>
    <meta charset="utf-8">
    <title>BCNC Gene Therapies for Hemophilia B Clinical Policy</title>
    <!--[if gte mso 9]>
    <xml>
        <w:WordDocument>
            <w:View>Print</w:View>
            <w:Zoom>90</w:Zoom>
            <w:DoNotPromptForConvert/>
            <w:DoNotShowInsertionsAndDeletions/>
        </w:WordDocument>
    </xml>
    <![endif]-->
    <style>
        body { font-family: 'Times New Roman', serif; font-size: 12pt; line-height: 1.15; margin: 1in; }
        .header { text-align: center; margin-bottom: 30px; border-bottom: 2px solid #003f7f; padding-bottom: 15px; }
        .company-name { font-size: 16pt; font-weight: bold; color: #003f7f; margin-bottom: 5px; }
        .policy-type { font-size: 14pt; color: #666; margin-bottom: 10px; }
        .policy-title { font-size: 18pt; font-weight: bold; color: #003f7f; margin-bottom: 15px; }
        .policy-info { font-size: 11pt; color: #333; }
        h1 { font-size: 14pt; font-weight: bold; color: #003f7f; margin-top: 25px; margin-bottom: 10px; border-bottom: 1px solid #003f7f; padding-bottom: 5px; }
        h2 { font-size: 13pt; font-weight: bold; color: #333; margin-top: 20px; margin-bottom: 8px; }
        h3 { font-size: 12pt; font-weight: bold; color: #333; margin-top: 15px; margin-bottom: 6px; }
        h4 { font-size: 12pt; font-weight: bold; color: #555; margin-top: 12px; margin-bottom: 6px; }
        ul, ol { margin: 10px 0; padding-left: 25px; }
        li { margin-bottom: 5px; line-height: 1.2; }
        .criteria-box { border: 1px solid #ccc; padding: 15px; margin: 15px 0; background-color: #f9f9f9; }
        .exclusion-box { border: 1px solid #d32f2f; padding: 15px; margin: 15px 0; background-color: #ffeaea; }
        table { width: 100%; border-collapse: collapse; margin: 15px 0; font-size: 11pt; }
        th, td { border: 1px solid #333; padding: 8px; text-align: left; vertical-align: top; }
        th { background-color: #003f7f; color: white; font-weight: bold; }
        .note { font-style: italic; color: #666; font-size: 10pt; margin: 10px 0; }
        .footer { margin-top: 30px; border-top: 1px solid #ccc; padding-top: 15px; font-size: 10pt; color: #666; }
    </style>
</head>
<body>

    

    <div class="header">
        <div class="company-name">Blue Cross Blue Shield of North Carolina</div>
        <div class="policy-type">Clinical Payment and Coding Policy</div>
        <div class="policy-title">Gene Therapies for Hemophilia B</div>
        <div class="policy-info">
            <strong>Policy Number:</strong> CPCPPHARM025<br>
            <strong>Version:</strong> 1.0<br>
            <strong>Approval Date:</strong> February 15, 2025<br>
            <strong>Plan Effective Date:</strong> May 1, 2025
        </div>
    </div>

    <h1>Policy Statement</h1>
    <p>Blue Cross and Blue Shield of North Carolina (BCBSNC) considers gene therapies for the treatment of Hemophilia B to be proven and medically necessary when specific clinical criteria are met as outlined in this policy. This policy applies to Beqvez (fidanacogene elaparvovec-dzkt) and Hemgenix (etranacogene dezaparvovec-drlb).</p>
    
    <p>If a conflict arises between this Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between this policy and any provider contract, the provider contract will govern.</p>

    <h1>Coverage Criteria</h1>

    <h2>Medical Necessity Requirements</h2>
    <div class="criteria-box">
        <p><strong>Gene therapy for Hemophilia B is considered medically necessary when ALL of the following criteria are met:</strong></p>
    </div>

    <h3>General Eligibility Criteria</h3>
    <ol>
        <li><strong>Age Requirement:</strong>
            <ul><li>Patient is 18 years of age or older</li></ul>
        </li>
        
        <li><strong>Hemophilia B Diagnosis:</strong>
            <ul>
                <li>Severe hemophilia B with endogenous factor IX levels less than 1% of normal (&lt; 0.01 IU/mL)</li>
                <li><strong>OR</strong></li>
                <li>Moderately severe hemophilia B with endogenous factor IX levels ≥ 1% to ≤ 2% (0.01-0.02 IU/mL) <strong>AND</strong> one of the following:
                    <ul>
                        <li>Current or historical life-threatening hemorrhage</li>
                        <li>Repeated, serious spontaneous bleeding episodes</li>
                    </ul>
                </li>
            </ul>
        </li>
        
        <li><strong>Prior Treatment History:</strong><br>
            One of the following must be documented:
            <ul>
                <li>Currently receiving chronic prophylactic Hympavzi (marstacimab-hncq) therapy</li>
                <li><strong>OR</strong></li>
                <li>Currently uses factor IX prophylaxis therapy <strong>AND</strong> has had a minimum of 50 exposure days to a factor IX agent</li>
                <li><strong>OR</strong></li>
                <li>Determined to be an appropriate candidate by a Hemophilia Treatment Center based on willingness to adhere to initial and long-term monitoring and management</li>
            </ul>
        </li>
    </ol>

    <h3>Exclusion Criteria</h3>
    <div class="exclusion-box">
        <p><strong>The following conditions EXCLUDE coverage for gene therapy:</strong></p>
        <ol>
            <li><strong>Inhibitor History:</strong>
                <ul>
                    <li>History of inhibitors to factor IX ≥ 0.6 Bethesda units (BU)</li>
                    <li>Positive screening for active factor IX inhibitors ≥ 0.6 Bethesda units (BU) prior to administration</li>
                </ul>
            </li>
            <li><strong>Previous Gene Therapy:</strong>
                <ul><li>Prior treatment with Beqvez, Hemgenix, or any other gene therapy for hemophilia B</li></ul>
            </li>
            <li><strong>Immune Tolerance Induction:</strong>
                <ul><li>Previous Immune Tolerance Induction (ITI) therapy</li></ul>
            </li>
        </ol>
    </div>

    <h3>Specific Requirements by Product</h3>
    <h4>For Beqvez (fidanacogene elaparvovec-dzkt):</h4>
    <ul>
        <li>No neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by FDA-approved test</li>
    </ul>

    <h4>For Hemgenix (etranacogene dezaparvovec-drlb):</h4>
    <ul>
        <li>Evaluation for preexisting neutralizing antibodies to adenovirus vector (AAV-5)</li>
        <li>Pre-existing anti-AAV5 neutralizing antibodies measured through CLIA-validated AAV5 Neutralizing Antibody Test</li>
        <li>No high anti-AAV antibody titers that may prevent treatment response</li>
    </ul>

    <h3>Medical Assessments Required</h3>
    <ol>
        <li><strong>Liver Health Evaluation:</strong>
            <ul>
                <li>Liver enzyme testing: ALT, AST, alkaline phosphatase, total bilirubin</li>
                <li>Hepatic ultrasound and/or elastography to rule out liver abnormalities</li>
            </ul>
        </li>
        <li><strong>Infectious Disease Screening:</strong>
            <ul>
                <li>HIV status: Negative OR positive with viral suppression (&lt; 200 copies/mL)</li>
                <li>Hepatitis B surface antigen: Negative</li>
                <li>Hepatitis C: Negative antibody OR positive antibody with negative HCV RNA</li>
                <li>Not currently using antiviral therapy for hepatitis B or C</li>
            </ul>
        </li>
    </ol>

    <h3>Provider and Facility Requirements</h3>
    <ol>
        <li><strong>Prescriber Qualifications:</strong>
            <ul>
                <li>Bleeding disorder specialist on staff at a federally designated Hemophilia Treatment Center (HTC)</li>
                <li>Listed in CDC's HTC directory</li>
            </ul>
        </li>
        <li><strong>Monitoring Commitments:</strong>
            <ul>
                <li><strong>Beqvez:</strong> ALT, AST, and factor IX activity monitoring weekly for minimum 4 months, then per prescribing information</li>
                <li><strong>Hemgenix:</strong> ALT, AST, and factor IX activity monitoring weekly for minimum 3 months, then per prescribing information</li>
            </ul>
        </li>
        <li><strong>Patient Counseling:</strong>
            <ul><li>Documentation of counseling regarding alcohol consumption risks post-treatment</li></ul>
        </li>
        <li><strong>Dosing Compliance:</strong>
            <ul><li>Dosing must be in accordance with FDA-approved labeling</li></ul>
        </li>
    </ol>

    <h3>Authorization Parameters</h3>
    <ul>
        <li><strong>Frequency:</strong> One treatment per lifetime maximum</li>
        <li><strong>Authorization Duration:</strong> No longer than 45 days from approval</li>
        <li><strong>Prior Authorization:</strong> Required</li>
    </ul>

    <h1>Limitations and Exclusions</h1>
    <p><strong>Gene therapy for Hemophilia B is NOT covered for:</strong></p>
    <ol>
        <li>Treatment of hemophilia A</li>
        <li>Repeat administration for hemophilia B treatment</li>
        <li>Treatment after previously receiving another factor IX gene therapy</li>
        <li>Routine combination with chronic prophylactic therapy</li>
        <li>Patients under 18 years of age</li>
        <li>Patients meeting any exclusion criteria listed above</li>
    </ol>

    <h1>Coding Information</h1>

    <h2>HCPCS Codes</h2>
    <table>
        <tbody><tr>
            <th>Code</th>
            <th>Description</th>
        </tr>
        <tr>
            <td>J1411</td>
            <td>Injection, etranacogene dezaparvovec-drlb (Hemgenix), per therapeutic dose</td>
        </tr>
        <tr>
            <td>J1414</td>
            <td>Injection, fidanacogene elaparvovec-dzkt (Beqvez), per therapeutic dose</td>
        </tr>
    </tbody></table>

    <h2>ICD-10-CM Diagnosis Codes</h2>
    <table>
        <tbody><tr>
            <th>Code</th>
            <th>Description</th>
        </tr>
        <tr>
            <td>D67</td>
            <td>Hereditary factor IX deficiency</td>
        </tr>
    </tbody></table>

    <p class="note"><em>Note: The inclusion of a code does not guarantee coverage. Benefit coverage is determined by the member-specific benefit plan document and applicable medical necessity criteria.</em></p>

    <h1>Documentation Requirements</h1>

    <h2>Prior Authorization Submission Must Include:</h2>
    <ol>
        <li><strong>Complete medical history including:</strong>
            <ul>
                <li>Hemophilia B diagnosis confirmation</li>
                <li>Factor IX activity levels</li>
                <li>Bleeding episode history</li>
                <li>Previous treatment regimens</li>
            </ul>
        </li>
        <li><strong>Laboratory Results:</strong>
            <ul>
                <li>Factor IX inhibitor testing</li>
                <li>Liver function tests</li>
                <li>Infectious disease screening results</li>
                <li>Viral vector antibody testing (product-specific)</li>
            </ul>
        </li>
        <li><strong>Provider Documentation:</strong>
            <ul>
                <li>HTC certification verification</li>
                <li>Treatment plan and monitoring schedule</li>
                <li>Patient counseling documentation</li>
            </ul>
        </li>
        <li><strong>Clinical Assessments:</strong>
            <ul>
                <li>Liver imaging results</li>
                <li>Treatment candidacy evaluation</li>
            </ul>
        </li>
    </ol>

    <h1>Quality Monitoring</h1>

    <h2>Ongoing Assessment Requirements</h2>
    <p>Prescribers must attest that patients will be assessed for:</p>
    <ul>
        <li>Factor IX expression levels</li>
        <li>Breakthrough bleeding episodes</li>
        <li>Factor IX product utilization</li>
        <li>Inhibitor development</li>
        <li>Adverse events</li>
    </ul>

    <p>BCBSNC may request documentation of patient assessments biannually for up to 5 years post-treatment for quality assurance purposes.</p>

    <h1>Background and Rationale</h1>
    <p>Hemophilia B is a rare, X-linked genetic bleeding disorder affecting approximately 1 in 40,000 individuals, representing about 15% of all hemophilia cases. The condition results from deficiency or dysfunction of coagulation factor IX, leading to prolonged bleeding episodes and potential life-threatening hemorrhages.</p>

    <p>Gene therapy represents a transformative treatment approach that introduces a functional copy of the factor IX gene to enable endogenous factor IX production, potentially reducing or eliminating the need for regular factor IX replacement therapy.</p>

    <p><strong>Beqvez</strong> utilizes AAVRh74var vector technology containing the high-activity FIX-R338L variant (Padua variant) to deliver the therapeutic gene to hepatocytes.</p>

    <p><strong>Hemgenix</strong> employs AAV5 vector containing the codon-optimized human factor IX gene with the Padua variant under liver-specific promoter control.</p>

    <p>Both therapies have demonstrated efficacy in reducing annualized bleeding rates in clinical trials of adults with moderate to severe hemophilia B.</p>

    <h1>Clinical Evidence Summary</h1>
    <p>Clinical efficacy has been established through:</p>

    <p><strong>Beqvez:</strong> Prospective, open-label, single-arm study (n=45) demonstrating non-inferiority in annualized bleeding rate reduction from 4.5 to 2.5 bleeds/year post-treatment.</p>

    <p><strong>Hemgenix:</strong> Open-label, single-arm study (n=54) showing significant reduction in annualized bleeding rate from 4.1 to 1.9 bleeds/year during months 7-18 post-treatment.</p>

    <h1>References</h1>
    <ol>
        <li>U.S. Food and Drug Administration. Beqvez (fidanacogene elaparvovec-dzkt) Prescribing Information. April 2024.</li>
        <li>U.S. Food and Drug Administration. Hemgenix (etranacogene dezaparvovec-drlb) Prescribing Information. November 2022.</li>
        <li>Miesbach W, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 2018;131(9):1022-1031.</li>
        <li>Von Drygalski A, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019;3(21):3241-3247.</li>
        <li>Division of Blood Disorders Gateway. HTC Directory. Centers for Disease Control and Prevention. Available at: https://dbdgateway.cdc.gov/HTCDirSearch.aspx</li>
    </ol>

    <h1>Policy History</h1>
    <table>
        <tbody><tr>
            <th>Approval Date</th>
            <th>Effective Date</th>
            <th>Summary of Changes</th>
        </tr>
        <tr>
            <td>02/15/2025</td>
            <td>05/01/2025</td>
            <td>New policy establishing coverage criteria for gene therapies for Hemophilia B</td>
        </tr>
    </tbody></table>

    <div class="footer">
        <h2>Contact Information</h2>
        <p>For questions regarding this policy, please contact BCBSNC Provider Services at 1-800-XXX-XXXX or visit the provider portal at bcbsnc.com.</p>
        
        <p class="note"><em>This policy is subject to change based on new clinical evidence, regulatory updates, and plan design modifications.</em></p>
        
        <p><strong>Proprietary Information of Blue Cross and Blue Shield of North Carolina. Copyright 2025 Blue Cross and Blue Shield of North Carolina.</strong></p>
    </div>

    <script>
        function downloadAsWord() {
            // Create a blob with the HTML content formatted for Word
            const htmlContent = `
<!DOCTYPE html>
<html xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns="http://www.w3.org/TR/REC-html40">
<head>
    <meta charset="utf-8">
    <title>BCNC Gene Therapies for Hemophilia B Clinical Policy</title>
    <!--[if gte mso 9]>
    <xml>
        <w:WordDocument>
            <w:View>Print</w:View>
            <w:Zoom>90</w:Zoom>
            <w:DoNotPromptForConvert/>
            <w:DoNotShowInsertionsAndDeletions/>
        </w:WordDocument>
    </xml>
    <![endif]-->
    <style>
        body { font-family: 'Times New Roman', serif; font-size: 12pt; line-height: 1.15; margin: 1in; }
        .header { text-align: center; margin-bottom: 30px; border-bottom: 2px solid #003f7f; padding-bottom: 15px; }
        .company-name { font-size: 16pt; font-weight: bold; color: #003f7f; margin-bottom: 5px; }
        .policy-type { font-size: 14pt; color: #666; margin-bottom: 10px; }
        .policy-title { font-size: 18pt; font-weight: bold; color: #003f7f; margin-bottom: 15px; }
        .policy-info { font-size: 11pt; color: #333; }
        h1 { font-size: 14pt; font-weight: bold; color: #003f7f; margin-top: 25px; margin-bottom: 10px; border-bottom: 1px solid #003f7f; padding-bottom: 5px; }
        h2 { font-size: 13pt; font-weight: bold; color: #333; margin-top: 20px; margin-bottom: 8px; }
        h3 { font-size: 12pt; font-weight: bold; color: #333; margin-top: 15px; margin-bottom: 6px; }
        h4 { font-size: 12pt; font-weight: bold; color: #555; margin-top: 12px; margin-bottom: 6px; }
        ul, ol { margin: 10px 0; padding-left: 25px; }
        li { margin-bottom: 5px; line-height: 1.2; }
        .criteria-box { border: 1px solid #ccc; padding: 15px; margin: 15px 0; background-color: #f9f9f9; }
        .exclusion-box { border: 1px solid #d32f2f; padding: 15px; margin: 15px 0; background-color: #ffeaea; }
        table { width: 100%; border-collapse: collapse; margin: 15px 0; font-size: 11pt; }
        th, td { border: 1px solid #333; padding: 8px; text-align: left; vertical-align: top; }
        th { background-color: #003f7f; color: white; font-weight: bold; }
        .note { font-style: italic; color: #666; font-size: 10pt; margin: 10px 0; }
        .footer { margin-top: 30px; border-top: 1px solid #ccc; padding-top: 15px; font-size: 10pt; color: #666; }
    </style>
</head>
<body>
${document.body.innerHTML.replace(/<button[^>]*>.*?<\/button>/gi, '')}
</body>
</html>`;

            const blob = new Blob([htmlContent], { type: 'application/msword' });
            const url = window.URL.createObjectURL(blob);
            const a = document.createElement('a');
            a.href = url;
            a.download = 'BCNC_Gene_Therapies_Hemophilia_B_Policy.doc';
            document.body.appendChild(a);
            a.click();
            document.body.removeChild(a);
            window.URL.revokeObjectURL(url);
        }
    </script>


</body>
</html>